

REMARKS

Claims 1-56 are presented in this application. In this amendment, claims 55 and 56 have been cancelled, and claims 4, 5, 7-10, 12, 13, 15-20, 23, 26, 28-30, 32, 35-39, 41-43, 46, 47, 49, 52, and 53 have been amended to remove multiple dependencies for the purpose of reducing fees.

Applicants have amended the specification for purposes of adding the priority information. Further, appropriate headings have been inserted in accordance to 37 CFR 1.77. Applicants have attached an Abstract on a separate sheet of paper as required by US practice.

It is respectfully submitted that the present application is in condition for allowance. An early consideration and Notice of Allowance are earnestly solicited.

The Commissioner is hereby authorized in this, concurrent, and future replies, to charge any fees or credit any overpayment, particularly including any fees required under 37 CFR Sect 1.16 or 1.17, and any necessary extension of time fees, to deposit Account No. 07-1392.

Respectfully submitted,


J. Scott Young
Attorney for Applicant
Registration No. 45,582

16
Date: 15 Dec 2005
GlaxoSmithKline
Corporate Intellectual Property
Five Moore Drive
P.O. Box 13398
Research Triangle Park, NC 27709-3398
Phone: 919-483-8160
Facsimile: 919-483-7988